Eupraxia Pharmaceuticals Reports Strong Histological Improvements in EoE Trial

summarizeSummary

Eupraxia Pharmaceuticals announced positive histological sub-score data from its Phase 1b/2a RESOLVE trial for EP-104GI in Eosinophilic Esophagitis, showing significant improvements in inflammation and fibrosis.

check_boxKey Events

• Positive Histological Data Released

  Eupraxia Pharmaceuticals announced the first release of EoEHSS sub-score data from its Phase 1b/2a RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE).

• Significant Improvements in Inflammation

  EoEHSS sub-scores for inflammation (EoEHSS-i) showed improvements in all reported cohorts at both 12 and 36 weeks, with the highest dose cohort demonstrating over 90% improvement.

• Fibrosis Markers Also Improved

  EoEHSS sub-scores for tissue architecture (fibrosis) (EoEHSS-a) improved across most cohorts at 12 and 36 weeks, with the highest dose cohort showing over 83% improvement.

• Data Presented at DDW Conference

  These positive results were presented this week at the Digestive Disease Week (DDW) conference in Chicago.

auto_awesomeAnalysis

This 6-K reports the first release of detailed EoEHSS sub-score data from the ongoing Phase 1b/2a RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE). The data demonstrates significant improvements in both inflammatory and architectural (fibrosis) markers, particularly at the highest dose tested. These histological findings are crucial as they directly measure tissue health and disease severity, complementing the previously reported positive endoscopic data. The consistent positive results across different measures strengthen the clinical profile of EP-104GI and de-risk the program as it progresses towards the Phase 2b top-line data expected in Q4 2026. This positive update provides further validation for the company's Diffusphere™ technology and its potential in treating EoE.